Fujifilm

Ripcord is a robotic digitization company that develops platforms and software to convert physical documents into digital, searchable data and streamlined workflows. Its Canopy solution uses artificial intelligence and machine learning to capture, enrich, and organize content, enabling enterprises to simplify processes and improve accuracy. The company combines sensors, automation, and vision-guided robots to create a digital twin of information, perform document scanning and recognition, and accelerate data capture, organization, and retrieval. This supports faster, higher-quality processing and moves organizations toward paperless document management and more efficient operations. Headquartered in Los Angeles, Ripcord was founded in 2014.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Founded in 1995, MicroChannel is a renowned provider of business solutions and technology, serving mid-sized businesses, corporate divisions, and government agencies. It assists clients in leveraging technology for commercial success by offering services such as customer relationship management, enterprise resource planning, managed IT services, and comprehensive business consultancy.

Inspirata, Inc. is an oncology informatics company dedicated to enhancing the cancer care experience for patients and clinicians. The firm provides innovative software solutions that utilize advanced artificial intelligence and natural language processing to streamline clinical trials and cancer registry operations. With over two decades of collaboration with the National Cancer Institute, Inspirata's proprietary AI and NLP engine powers key products such as Trial Navigator, which automates clinical trial matching, and E-Path Plus, a leading solution for cancer registry reporting and data abstraction. These tools are used by numerous healthcare institutions worldwide, aiming to improve patient outcomes and support healthcare professionals in their fight against cancer.

24M Technologies specializes in energy storage systems for grid and transportation applications. It offers innovative binder-free semisolid electrodes and unit cells, eliminating the need for traditional hydro or pyrometallurgical processes in battery recycling.

Cuorips Inc. is a medical care company based in Chuo, Japan, with an additional office in Osaka. Founded in 2017, it focuses on the research, development, and commercialization of iPS cell-derived cardiomyocyte sheets and various cell therapeutic products. The company offers manufacturing and sales of cellular and tissue-based products, along with contract development and manufacturing services. Cuorips aims to advance medical treatments through innovation in cell processing and therapeutic applications.

Rege Nephro is a Kyoto-based biotechnology company focused on renal disease therapeutics. It conducts research and development, production, and marketing of therapies based on nephron progenitor cells, and develops kidney organoids used to screen nephrotoxicity in drug discovery. The company is leveraging induced pluripotent stem cell technology from the Center for iPS Cell Research and Application at Kyoto University to develop cell-based therapies for kidney conditions, along with potential applications for liver and pancreas diseases. Founded in 2019, Rege Nephro aims to reduce dialysis dependence by addressing renal failure through regenerative approaches.

Nanox Imaging is a Gibraltar-based company founded in 2011 that specializes in advanced imaging technology for medical, security, and telecommunications applications. The company is pioneering next-generation X-ray emitters utilizing innovative nanotechnology to modernize X-ray imaging, enabling the development of novel 3D imaging systems with superior performance. Central to Nanox's offerings is the Nanox System, which provides a preventative healthcare service known as Medical Screening As A Service (MSaaS). The company has leveraged over two decades of research and development, investing more than $1 billion to create proprietary cold cathode technology that enhances X-ray imaging capabilities. This technology features a chip composed of nano-scale structures, designed through unique nanofabrication techniques, which supports various medical imaging applications and is complemented by additional technologies to maximize its practical benefits in real-world scenarios.

Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.

Fuji Xerox New Zealand is part of a global enterprise group that specializes in business and document management services. The company offers a comprehensive suite of technologies and solutions, including digital printing, document management, and business process outsourcing. By helping businesses reduce printing costs, streamline processes, and automate tasks, Fuji Xerox New Zealand aims to enhance operational efficiency and drive cost savings. The organization is committed to fostering long-term relationships with its clients and communities, and it actively supports various environmental, educational, and sporting initiatives. Through its scalable and cost-effective solutions, Fuji Xerox New Zealand seeks to empower local businesses to grow and transform.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

PuREC develops innovative cell therapy technologies aimed at enhancing treatment efficacy. The company focuses on rapidly evolving cell therapies and mesenchymal stem cells, targeting specific conditions such as hypophosphatasia (a rare bone formation deficiency) and spinal canal stenosis caused by disc herniation.

Junten Bio is a biotechnology company focused on the research and development of cell medicines utilizing regenerative medicine technology. The company aims to enhance medical care through innovative products that address the challenges of immune rejection in organ transplantation. By investigating the mechanisms behind immune rejection, Junten Bio works on developing cell therapies that can minimize the side effects associated with immunosuppressive treatments, ultimately helping patients achieve a better quality of life while reducing overall medical expenses.

LPixel is a Tokyo-based developer of life science image analysis software and cloud-enabled AI systems. The company offers an integrated platform for life science imaging that combines AI with traditional image processing to perform morphological analysis, automated cell counting, and automatic image classification, helping researchers detect anomalies in medical images. Its offerings include LPixel ImageJ Plugins, LP-exam for detecting image manipulations and plagiarism, and IMACEL, a cloud and AI-based image analysis system. LPixel also runs education programs for life science researchers and students. The company originated as a spin-out from the University of Tokyo and focuses on enabling efficient research through advanced image analysis tools.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, that focuses on designing and developing innovative therapeutic products with a unique delivery technology. Established in 2016, the company specializes in enabling ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract without the need for encapsulation. Suono Bio aims to transform the treatment landscape for difficult-to-treat diseases, particularly those mediated by inflammatory processes, by facilitating effective therapy delivery that enhances patient recovery from gastrointestinal conditions.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

IS Japan, founded in 1989, manufactures in vitro fertilization products, products for cell culture, and products for research on regenerative medicine and cell therapy, and distributes Irvine Scientific's products in and outside Japan.

Xerox is a global leader in document management technology and services. It offers a wide range of products and solutions, including printing systems, digital presses, multifunction devices, copiers, fax machines, workflow solutions, mobile apps, cybersecurity services, automation tools, and data analytics.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Cyfuse Biomedical specializes in developing tissue fabrication systems and cell-based products for global research institutions. It offers a robotic 3D BioFabrication system, producing various tissue grafts for therapeutic use, drug development, and research purposes. Founded in 2010, the company is headquartered in Tokyo, Japan.

Tokiwa Bio Inc. is a Japanese company based in Tsukuba that specializes in the development and manufacturing of drugs for regenerative medicine, particularly focusing on gene therapy. Founded in 2014, the company utilizes artificially synthesized vectors to introduce multiple genes into the cytoplasm of cells without causing damage to the existing genetic material. This innovative approach facilitates the creation of gene therapy drugs aimed at treating rare diseases, including hemophilia and ischemia. In addition to its gene therapy efforts, Tokiwa Bio also produces biopharmaceuticals, antibody drugs, and research reagents, positioning itself as a key player in the biopharmaceutical industry.

BONAC Corporation is a biotechnology company focused on the research, development, and commercialization of nucleic acid pharmaceutical products utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with a branch office in Tokyo, BONAC specializes in manufacturing nucleic acid drug substances and providing comprehensive drug development support. The company aims to enable drug and cosmetic manufacturers to access innovative drug substances that address unmet medical needs through its expertise in nucleic acid medicines and RNA technology.

RegCell focuses on developing innovative therapies by modulating or controlling the immune system. Its primary objective is to treat patients with autoimmune diseases and cancer.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Ultra Pure Solutions, Inc. is one of the largest manufacturers of high purity chemicals in North America.

FUJIFILM TeraMedica, Inc., based in Milwaukee, WI, is a prominent healthcare informatics company specializing in vendor-neutral, enterprise-wide solutions for medical image management. Founded in 2001, the company gained recognition for deploying the first cross-departmental, patient-centric clinical image archive at Mayo Clinic in 2003. TeraMedica's software has since been implemented in over 600 healthcare facilities across six continents, demonstrating its adaptability and commitment to meeting customer needs. The company's focus on providing comprehensive clinical content management services positions it as a leader in the healthcare informatics sector, dedicated to enhancing the efficiency and accessibility of medical imaging for healthcare enterprises.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

SonoSite, Inc. is a leading provider of hand-carried ultrasound systems, specializing in the portable ultrasound market. The company has revolutionized diagnostic imaging by developing systems that deliver high-quality performance traditionally found in larger, expensive machines but in a compact, laptop-sized format. This innovation allows for enhanced efficiency in existing clinical settings and introduces new point-of-care applications in areas where ultrasound was previously impractical due to size or cost. SonoSite's products cater to various medical fields, including radiology, cardiology, obstetrics and gynecology, emergency medicine, and critical care. With over 40,000 systems sold since its inception in 1999, the company is recognized for its exceptional imaging performance, user-friendly design, and durability, ultimately contributing to safer and more affordable healthcare delivery in hospitals and clinical environments.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

Dimatix is a world leader in the research, development, manufacture and sale of printheads used in industrial inkjet printers, which are increasingly being used in such fields as outdoor advertising and packaging materials. As such, the company supplies printheads and provides after-sales service to printer manufacturers and various other users. Using MEMS1, Dimatix has developed advanced piezoelectric printheads2 that feature superior quality and excellent durability.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

Sericol is a global corporation engaged in the development, manufacturing and sale of inks for screen and package printing as well as industrial inkjet inks and materials. With inks for screen printing and wide format digital UV inkjet inks, the company maintains a leading market share position worldwide.